Hair loss linked to GLP-1 weight-loss drugs in new study
TL;DR Summary
A BMJ study of about 50,000 people finds GLP-1 receptor agonists (used for diabetes and obesity, including Wegovy, Ozempic and Mounjaro) are associated with a higher risk of hair loss compared with other diabetes drugs; after adjustment, risk was 37% higher than SGLT-2 inhibitors and 68% higher than DPP-4 inhibitors, with indications that the hair loss is non-scarring and may relate to weight loss, micronutrient deficiencies, or hormonal changes; regulators are reviewing safety signals.
- Weight loss drugs linked to loss of hair in major new study The Independent
- Hair loss with GLP-1 drugs is rare, but real, studies find Reuters
- New studies reveal rare but real risk of GLP-1 drugs New York Post
- Weight loss drugs linked to increased risk of hair loss, researchers say Sky News
- Study Finds a Worrying New Side Effect of GLP-1 Drugs That No One's Talking About ScienceAlert
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
13 min
vs 14 min read
Condensed
97%
2,715 → 74 words
Want the full story? Read the original article
Read on The Independent